NASDAQ:ITCI - Intra-Cellular Therapies Stock Price, Forecast & News

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies Inc (NASDAQ:ITCI) posted its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating the Zacks' consensus estimate of ($0.80) by $0.17. View Intra-Cellular Therapies' Earnings History.

Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Intra-Cellular Therapies.

10 equities research analysts have issued 1 year target prices for Intra-Cellular Therapies' stock. Their forecasts range from $16.00 to $73.00. On average, they expect Intra-Cellular Therapies' stock price to reach $37.75 in the next twelve months. This suggests a possible upside of 53.7% from the stock's current price. View Analyst Price Targets for Intra-Cellular Therapies.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intra-Cellular Therapies.

News coverage about ITCI stock has been trending somewhat positive on Friday, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Intra-Cellular Therapies earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Intra-Cellular Therapies.

Intra-Cellular Therapies saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 6,540,000 shares, a drop of 21.9% from the January 15th total of 8,370,000 shares. Based on an average daily trading volume, of 2,790,000 shares, the short-interest ratio is currently 2.3 days. Currently, 14.0% of the company's stock are short sold. View Intra-Cellular Therapies' Current Options Chain.

Some companies that are related to Intra-Cellular Therapies include United Therapeutics (UTHR), Global Blood Therapeutics (GBT), Evotec (EVTCY), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Zai Lab (ZLAB), PTC Therapeutics (PTCT), SAGE Therapeutics (SAGE) and Ultragenyx Pharmaceutical (RARE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Synergy Pharmaceuticals (SGYP), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Crispr Therapeutics (CRSP), Gilead Sciences (GILD) and Clovis Oncology (CLVS).

Intra-Cellular Therapies' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (11.41%), State Street Corp (2.01%), Candriam Luxembourg S.C.A. (1.61%), Schroder Investment Management Group (1.36%), Geode Capital Management LLC (1.15%) and Rhenman & Partners Asset Management AB (0.90%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.

ITCI stock was sold by a variety of institutional investors in the last quarter, including Samlyn Capital LLC, Schroder Investment Management Group, Rhenman & Partners Asset Management AB, State Street Corp, Candriam Luxembourg S.C.A., Geode Capital Management LLC, General American Investors Co. Inc. and Credit Suisse AG. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Andrew Satlin, Lawrence J Hineline, Mark Neumann, Michael Halstead and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.

ITCI stock was purchased by a variety of institutional investors in the last quarter, including DCF Advisers LLC, FMR LLC, First Midwest Bank Trust Division, Goldman Sachs Group Inc., UBS Group AG, Raymond James & Associates, Palo Alto Investors LP and TD Asset Management Inc.. View Insider Buying and Selling for Intra-Cellular Therapies.

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ITCI stock can currently be purchased for approximately $24.56.

Intra-Cellular Therapies has a market capitalization of $1.36 billion and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-155,130,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe.View Additional Information About Intra-Cellular Therapies.

The official website for Intra-Cellular Therapies is http://www.intracellulartherapies.com/.

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]